Biotechnology
Medical
Health

Aurinia Pharmaceuticals

$6.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.21 (3.22%) Today
-$0.14 (-2.08%) After Hours

Why Robinhood?

You can buy or sell AUPH and other stocks, options, ETFs, and crypto commission-free!

About

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Employees
39
Headquarters
Victoria, British Columbia
Founded
1993
Market Cap
576.27M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
652.40K
High Today
$6.77
Low Today
$6.56
Open Price
$6.57
Volume
242.11K
52 Week High
$7.85
52 Week Low
$5.06

Collections

Biotechnology
Medical
Health
Canada
Pharmaceutical
Therapy
Technology
2013 IPO

News

Seeking AlphaMay 14

Aurinia Pharmaceuticals, Inc. CEO Peter Greenleaf on Q1 2019 Results - Earnings Call Transcript

Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Glenn Schulman - Investor Relations Richard Glickman - Emeritus Chairman & Chief Executive Officer Peter Greenleaf - Chief Executive Officer Dennis Bourgeault - Chief Financial Officer Neil Solomons - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Leerink Ed Arce - H.C. Wainwright Operator Greetings, and welcome to the Aurinia Pharmaceuticals First Qu...

922
Seeking AlphaMay 10

Aurinia And Voclosporin In Lupus Nephritis: An Update

This was probably the best time to change leadership, because 2019 could be a transformational year for Aurinia, if the Phase 3 trial of voclosporin in lupus nephritis is successful.

314
Yahoo FinanceMay 9

Here’s What Hedge Funds Think About Aurinia Pharmaceuticals Inc (AUPH)

As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them.

1,282

Earnings

-$0.21
-$0.15
-$0.10
-$0.04
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.14 per share
Actual
-$0.14 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.